Omeros (NASDAQ:OMER) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Omeros (NASDAQ:OMER - Free Report) from a hold rating to a sell rating in a report released on Friday morning.

Several other equities research analysts have also issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research note on Friday, May 16th. D. Boral Capital restated a "buy" rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, May 13th. Finally, HC Wainwright started coverage on shares of Omeros in a research note on Tuesday, June 10th. They set a "buy" rating and a $9.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Omeros Stock Performance

NASDAQ:OMER traded down $0.20 on Friday, hitting $3.00. The stock had a trading volume of 1,236,728 shares, compared to its average volume of 713,388. The stock has a market cap of $175.77 million, a P/E ratio of -1.13 and a beta of 2.21. Omeros has a 1 year low of $2.97 and a 1 year high of $13.60. The firm's fifty day simple moving average is $4.45 and its two-hundred day simple moving average is $7.15.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Equities research analysts predict that Omeros will post -3.09 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new position in Omeros in the 1st quarter valued at approximately $357,000. Trexquant Investment LP purchased a new position in Omeros in the 1st quarter valued at approximately $88,000. Hsbc Holdings PLC purchased a new position in Omeros in the 1st quarter valued at approximately $142,000. Wellington Management Group LLP purchased a new position in Omeros in the 1st quarter valued at approximately $1,118,000. Finally, Nuveen LLC purchased a new position in Omeros in the 1st quarter valued at approximately $938,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.